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A spectrometric method for the determination of L-carnitine has
been developed based on the reaction of the 5,51 dithiobis-(2-
nitrobenzoic) acid (DTNB) and adapted to a Technicon RA-
2000 automatic analyser Qu[mica Farmacutica Bayer, S.A.).
The detection limit of the method is 13.2#tool/l, with a
measurement interval rangingfrom 30 to 320 #moll1. Imprecision
and accuracy are good even at levels close to the detection limit
(coeffcient of variation of 5.4% for within-run imprecision for a
concentration of 35#tool/l). A good correlation was observed
between the method studied and the radiometric method. The
method evaluated has suffcient analytical sensitivity to diagnose
carnitine deficiencies. The short time period required for sample
processing (30 samples in 40rain), the simple methodology and
apparatus, the ease ofpersonnel training and the low cost of the
reagents make this method a good alternative to the classical
radiometric method for evaluating serum I-carnitine in clinical
laboratories without radioactive installations.
Introduction
To diagnose these diseases, L-carnitine has to be quanti-
fied in peripheral blood and tissues. Several methods
have been developed for this: spectrometric [10, 11],
radiometric [12, 13], enzymatic [14], fluorometric [15,
16], chromatographic [17] and mass spectrometry 18].
Since the main interest in determining L-carnitine is for
the evaluation of deficiencies, the methods used require
analytical sensitivity. This condition is difficult to achieve
with spectrometric and enzymatic methods, since they
often have high coefficients of variation when used at
levels close to the detection limit of the method. None-
theless, these methods are the most appropriate for work-
ing in a routine clinical biochemical laboratory, given
that they do not require high technology equipment,
radioactive installations or highly specialized personnel.
In order to improve analytical sensitivity, precision and
accuracy of the spectrometric method for evaluating
carnitine, the authors adapted the 5,51-dithiobis-(2-ni
trobenzoic)acid method (DTNB) of Marquis and Fritz
[10] to an automatic Technicon RA-2000 (Quimica
Farmacutica Bayer, S.A.) analyser. The potential of
the new method was compared with the classical radio-
metric method proposed by Cederblad and Lindstedt
[13], and modified by garth et al. [19].
I-Carnitine (3-hydroxy-4-trimethyl butyric amino acid)
is a synthesized quaternary amine from methionine and
lysine [1, 2] found in the human liver, brain and kidney
[3]. It is an essential cofactor for the transportation of
long chain fatty acids through the mitochondrial mem-
brane [4] thereby contributing to the beta-oxidation of
the same in the liver, heart and skeletal muscle [5]. It also
modulates the intracellular concentration of CoA and
acetyl-CoA [6] and eliminates such non-physiologic acyl
groups as the benzoic, pivalic and valproic acid [7].
A deficiency of I-carnitine means that the long chain
fatty acids will not be oxidized. Clinical manifestation of
this dysfunction is presented as myopathy, which may
range from simple muscular weakness or slight intoler-
ance to exercise to fatal encephalopathic episodes with
hepatic dysfunction or even cardiomyopathy.
Primary I-carnitine deficiencies have been classified into
two categories [8, 9]: deficiencies of exclusively muscular
localization, and those of systemic involvement. Second-
ary I-carnitine deficiency, however, is the most common
and is associated with pregnancy, malnutrition and
cachexia, hepatic cirrhosis, Reye’s syndrome, kidney
insufficiency with haemodialysis, Fanconi syndrome, pro-
longed intravenous nutrition, anorexia nervosa, treat-
ments with valproic acid and endocrinologic disorders,
etc.
Materials and methods
Principle of the method
The method, which was initially described by Marquis
and Fritz [10], is based on the reaction catalysed by the
carnitine acetyltransferase (CAT) enzyme (EC2.3.1.7)
acting on I-carnitine:
CAT
I-carnitine + acetyl-CoA acetyl-carnitine +
coenzyme A
The free coenzyme A combines with the 5,51-dithiobis
(2-nitrobenzioc) acid forming a fenolate ion spectrome-
trically measured at 405 nm.
Reagents and work solutions
Reagents
1M Tris HC1, pH 7.8 (Merck cat no. 8382). Stable for
at least six months stored between 2 and 8C.
5,51-Dithiobis-(2-nitrobenzoic) acid (BoehringerMann-
heim, cat no. 104477) at a concentration of 12.5mM in
potassium carbonate at 1%, pH 8. Frozen in aliquots;
stable for six months stored at -20C.
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15mM Acetyl-coenzyme A (Boehringer Mannheim
cat. no. 101893). Frozen in aliquots; stable for two
months at -20C.
50mM Ethylene diamine tetraacetic acid disodium
salt, pH 8 (Titriplex III, Merck cat. no. 8418). Stable
for at least six months stored at 4C.
20U/ml Carnitine acetyltransferase (EC 2.3.1.7)
(Boehringer Mannheim cat. no. 103241, specific
activity 80U/mg, 25C) in phosphate buffer 0.5 M,
pH 7.5. Diluted 1:50 in distilled water; stable for six
months at 4C.
L-Carnitine internal standard: L-carnitine (Boehringer
Mannheim cat. no. 836567) of 35, 77, 155, 179, 275,
and 310 gmol/L. Frozen in aliquots; stable for at least
six months at 20C.
Working solutions
Reagent solution 1:0.04mM tris-HC1 buffer, 0.05M
5,51-dithiobis-(2-nitrobenzoic) acid, 0.06mM acetyl-
coenzme A and 0.5mM ethylene diamine tetraacetic
acid. Prepare immediately before assay.
Reagent solution 2: 0.4U/mL carnitine acetyltrans-
ferase.
Automated assay: The working conditions in the RA-2000
analyser were as follows: type of reaction: end-point with
sample blank; specimen volume: 30 gl; volume of the first
reagent: 350gL; volume of the second reagent: 50gL;
wavelength: 405 nm; preincubation time: 15s; Incuba-
tion time; 8 min; second reagent addition time: min;
work temperature: 37C.
Calibration method: The method was calibrated with an L-
carnitine aqueous solution of 155 gmol/1.
Quality control: Standards of L-carnitine were processed
simultaneously with the problem samples. The assay was
considered exact when the values of the standards were
within +/-10%. Imprecision was controlled with a serum
pool.
Subjects: To study the reference values of the method, the
blood of 100 patients from the Department of Preventive
Medicine of the Hospital was used. Blood extraction was
carried out after 8 h of fasting. All the subjects in whom
the presence of associated diseases, toxic habits or drug
ingestion were observed were discarded.
Sixty of these values were used to study the correlation of
the method in which serum from 14 pregnant women, 21
patients on haemodialysis, three patients with hepatic
cirrhosis, 10 with morbid obesity and 12 undergoing
parenteral nutrition were also included.
Specimens: The blood samples (5 ml) were extracted by the
Vacutainer system in a dry tube without additives.
Following retraction of the clot, the samples were cen-
trifuged for 10 min at 3000 rpm. The resulting serum was
deproteinized following the procedure described by
Rodriguez-Segade et al. [20]: approximately ml of
serum was kept in a water bath at 100C for 5 min. After
being maintained at -20C for 40min the serum was
pricked with a needle tip until totally thawed and
centrifuged at 15 000rpm for 15 min. The clear super-
natant obtained after centrifugation was the specimen
used to determine free carnitine.
Evaluation of the method: The analytical interval and the
detection limit of the method were evaluated following
the directions of the Societfi Franaise de Biologie
Clinique [21]. To calculate the analytical interval stan-
dard aqueous solutions of L-carnitine were used. The
detection limit was established following the processing of
10 specimens of distilled water. With the mean (md) and
the standard deviation (SD) the detection limit for an o
and/3 risk of 5% was calculated (Ld md + K SD).
The recommendations of the European Committee for
Clinical Laboratory Standards (ECCLS) were followed
for the study of the imprecision and inaccuracy of the
method [22].
To determine the analytical recovery, increasing quan-
tities of L-carnitine were added to different aliquots of
sera pool. The dilution effect was corrected by adding the
same volume of saline solution to aliquot lanes. The
reference values of the method were obtained following
the recommendations of the Panel ofExperts of the IFCC
in reference values [23].
Correlation of the study method with the radiometric method: L-
Carnitine was determined in 120 samples simultaneously
by two methods: the study method and a radiometric
method. The latter was a modification of the method by
Cederblad and Lindstedt [18] proposed by Barth et al.
[19].
Statistical methods: Mean, standard deviation and coeffi-
cient of variation for studying the accuracy, imprecision
and detection limit. Deming’s regression analysis was also
used to study the correlation of methods.
To calculate the reference values of the method, the 2.5,
50 and 97.5 percentiles (P2.5, P50, and P97.5) were used.
Practicability study: To assess the practicability of the
method, the following aspects were taken into account:
the installations and apparatus required, training of
personnel, time and performance of the assay (prepara-
tion of reagents, treatment of the sample, processing of
specimen), expiry dates and costs of the reagents. The
practicability of the method was compared with that of
the radiometric method (taken as the reference).
Results
Detection limit and analytical interval. The detection limit
established for the method was 13.2 gmol/1. The analy-
tical interval of the method ranged from 30 to 320 gmol/1.
Figure shows the slope of linear regression of the least
squares (y 0.9 x + 6.0; r 0.98) established among the
theoretical values (x) of the six L-carnitine reference
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standards, processed in triplicate over three consecutive
days, and the values found (y).
Imprecision and inaccuracy. Table demonstrates the with-
in-run and between-run coefficients of variation of the
aqueous internal standards of L-carnitine at three con-
centration levels, as well as those of the serum specimen.
The percentages of inaccuracy with respect to the
theoretical value (table 2) did not exceed 10%.
Analytical recovery study. Analytical recovery of L-carnitine
accounted for 89 to 97% (see table 3).
Correlation with the radiometric method. The slope of the
linear regression of least squares between the colorimetric
method (y) and the radiometric method (x) was
y 1.24x + 8.60 and linear coefficient of correlation of
Pearson was 0.77 (see figure 2). Deming’s regression
analysis (b 1.3528, a 3.969) shows that the method
measures values higher than the radiometric method.
Practicability of the method. Table 4 shows the features
studied in order to evaluate the practicability of the
method in comparison with the classical radiometric
method.
Reference values. The reference interval for the whole
population studied ranged from 52 to 96.8 gmol/1.
Table 1. Method imprecision.
Within-run Between-run
cv (%) cv (%)
Aqueous L-carnitine 20 4.9 5.4
solution (35 gmol/1)
Aqueous L-carnitine 20 4.6 4.9
solution (170 lamol/1)
Aqueous L-carnitine 20 1.5 4.3
solution (275 lamol/1)
Discussion
The main clinical application of the evaluation of L-
carnitine is for evaluating L-carnitine deficiency in hu-
man serum or tissues. The enzymatic [14] and spectro-
metric methods [10] for quantifying this biochemical
magnitude generally have low analytical sensitivity for
evaluating L-carnitine levels below the reference interval
of the method. The coefficients of variation in these
ranges are high. The problem is exacerbated with the
deproteinization process required for the sample [10, 24],
since the treatment with the deproteinization method
Table 2. Inaccuracy.
Within-run
Concentration (theoretical) in Concentration found
#moll1 n (#moll1) Inaccuracy (%)
Between-run
Concentration found
(#moll1) Inaccuracy (%)
77 2O 72.2 6.2
155 20 164.5 6.1
310 20 300 3.3
74 3.9
163 5.1
301 2.9
Table 3. Recovery study.
Serum pool L-carnitine Theoretical carnitine Carnitine concentration
(#moll1) added (#mol/l) concentration (#moll1) found (#moll1) Recovery (%)
68.3 186 254 228 90
68.3 124 192 170 89
34.1 62 96 95 97
16.7 31 47.7 46 95
Table 4. Practicability of the spectrometric method versus the radiometric method.
Radiometric method Spectrometric method
Type of installation
Apparatus
Personnel training
Response time
Sample pretreatment
Sample processing
Reagents
Reagent preparation
Expiry date of reagents
Cost of reagents
Radioactive
B-Scintillation counter
Refridgerated centrifuge
Requires title of radiosotope manipulator
24h
Not required
Manual: 2 h and
posterior radioactivity count
Longer and more difficult than in the radiometry
Long
Conventional
Automatic analyser or
spectrometer
Relatively simple
Approximately 2 h
50 min
Automatic: 9 min.
Relatively simple
Six months
2.3-fold lower than radiometric method
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Figure1. Analytical interval: reference line (--)
y bx (b 1) and 2 standard deviations of reference line
y x (+), (). The points from 30 to 320 #mol/1 on the
experimental line (y 0.9 x + 6) (---) cross either directly or at
least in the range of their 2 standard deviations the reference line.
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Figure 2. Correlation between the radiometric and the colorimetric
method.
often leads to an even greater decrease in carnitine
concentration.
With the proposed method the analytical sensitivity at
low levels markedly improved, the between-run coeffi-
cient of variation for a concentration of 35 gmol/1 was
5.4%. This concentration is lower than the low interval
of the method reference value (52 gmol/1) and is close to
the 13.2 gmol/1 of the detection limit. The improvement
achieved is due to the automatization process of the
spectrometric method of the 5,5t-dithiobis-(2-nitroben
zoic) acid, and also to the use of thermic deproteinization
described by Rodriguez-Segade et al. [20] which, among
other advantages, avoids any dilution of the sample. On
adapting the technique by Marquis and Fritz [10], an
automatized method is able to markedly save the volume
of the deproteinized Sample. Thirty microlitres were used
versus the ml required by the original technique.
From a practical point of view, the adapted method has
advantages over the radiometric method. The results
were obtained quickly, with 30 deproteinized samples
being processed in 40 min. The cost of the reagents is 2.3-
fold less than that of the radiometric method. Moreover,
training of personnel for performing this technique is
relatively simple and the apparatus required are gener-
ally found in a conventional clinical laboratory. The
radiometric methods used as reference methods (because
of their greater analytical sensitivity) present the incon-
veniences of using radioisotopes requiring radioactive
installations which not all clinical laboratories possess.
Thus, the evaluation presented demonstrates excellent
applicability, particularly for laboratories without radio-
active installations.
The method developed and presented in this study has
sufficient analytical sensitivity to evaluate defiencies in
serum carnitine. This method may substitue the classical
radiometric method and should be considered in clinical
laboratories without radioactive installations.
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